{
    "hands_on_practices": [
        {
            "introduction": "The remarkable adaptability of HIV stems from its genetically unstable nature. This practice problem models this core feature by asking you to calculate the expected number of mutations introduced during a single replication cycle, based on the virus's genome size and the known error rate of its reverse transcriptase. By applying basic probability principles, you will quantify the constant generation of genetic diversity that fuels the evolution of viral \"quasispecies,\" a central concept in HIV pathogenesis. ",
            "id": "4426965",
            "problem": "An investigator is studying Human Immunodeficiency Virus type 1 (HIV-1) replication dynamics in lymphoid tissues to understand how quasispecies arise during chronic infection in Acquired Immune Deficiency Syndrome (AIDS). The HIV-1 genome length is approximately $9.7$ kilobases, and the reverse transcriptase (RT) average base misincorporation probability per replication cycle is approximately $3 \\times 10^{-5}$ per base per cycle. Treat base misincorporations as rare and independent across sites. Using only core definitions from probability (independent Bernoulli trials, linearity of expectation) and the rare-event approximation for aggregate point mutations in a genome, derive the expected number of point mutations per full-genome replication cycle for a single virion. Then, based on the magnitude of this expectation, explain how such mutation input supports quasispecies diversification in lymphoid tissues characterized by high viral turnover and immune selection.\n\nReport the expected number as a single real-valued number rounded to three significant figures. No units are required for the final numerical answer.",
            "solution": "The problem is scientifically valid and well-posed. All the necessary parameters and assumptions are provided, and they are consistent with established knowledge in virology and pathology. The problem asks for the derivation of an expected value using fundamental principles of probability and an explanation of its biological significance.\n\nFirst, we formalize the problem. Let $L$ be the length of the HIV-1 genome in bases and $p$ be the average probability of a base misincorporation (point mutation) per site during one replication cycle.\n\nThe given values are:\n- Genome length, $L \\approx 9.7$ kilobases. We convert this to bases:\n$$ L = 9.7 \\times 10^3 = 9700 \\text{ bases} $$\n- Misincorporation probability, $p \\approx 3 \\times 10^{-5}$ per base per cycle.\n\nThe problem states that base misincorporations are independent across all sites. The process of mutation at each of the $L$ base positions can be modeled as an independent Bernoulli trial. For each base $i$ (where $i$ ranges from $1$ to $L$), we define an indicator random variable, $X_i$, such that:\n$$\nX_i =\n\\begin{cases}\n1 & \\text{if a mutation occurs at site } i \\\\\n0 & \\text{if no mutation occurs at site } i\n\\end{cases}\n$$\nThe probability of a mutation at any single site is given as $p$. Therefore, the probability distribution for each $X_i$ is:\n$$ P(X_i = 1) = p = 3 \\times 10^{-5} $$\n$$ P(X_i = 0) = 1 - p $$\nThe expected value of a single Bernoulli trial $X_i$ is:\n$$ E[X_i] = (1 \\times P(X_i=1)) + (0 \\times P(X_i=0)) = P(X_i=1) = p $$\n\nThe total number of new point mutations in the entire genome during one replication cycle, let's call it $M$, is the sum of the mutations at each site. Thus, $M$ is the sum of all the indicator random variables:\n$$ M = \\sum_{i=1}^{L} X_i $$\nThe problem asks for the expected number of point mutations, which is $E[M]$. We can find this using the property of linearity of expectation, which states that the expectation of a sum of random variables is the sum of their individual expectations. This property holds regardless of whether the variables are independent.\n$$ E[M] = E\\left[\\sum_{i=1}^{L} X_i\\right] = \\sum_{i=1}^{L} E[X_i] $$\nSince the expectation for each site is the same ($E[X_i] = p$ for all $i$), the sum becomes:\n$$ E[M] = \\sum_{i=1}^{L} p = L \\times p $$\nThis derivation uses the core definition of linearity of expectation as requested. The problem also mentions the \"rare-event approximation\". Since the mutation probability $p$ is very small ($3 \\times 10^{-5}$) and the number of trials $L$ is large ($9700$), the total number of mutations $M$ is well-approximated by a Poisson distribution with parameter $\\lambda = L \\times p$. The expected value of a Poisson-distributed random variable with parameter $\\lambda$ is $\\lambda$ itself, which confirms our result $E[M] = L \\times p$.\n\nNow, we substitute the given numerical values to calculate the expected number of mutations:\n$$ E[M] = L \\times p = (9700) \\times (3 \\times 10^{-5}) $$\n$$ E[M] = 29100 \\times 10^{-5} = 0.291 $$\nThe question requires the answer to be rounded to three significant figures. The calculated value $0.291$ is already in this form.\n\nNext, we explain the biological significance of this result in the context of HIV-1 quasispecies diversification.\n\nThe expected value of $0.291$ mutations per replication cycle is a critically important quantity. It means that, on average, nearly one new mutation is introduced into the viral genome for every three to four replication cycles ($1 / 0.291 \\approx 3.44$). While this number may seem small, it must be considered in the context of the extremely high rate of viral production (turnover) in an infected individual, particularly in lymphoid tissues. HIV-1 can produce upwards of $10^{10}$ new virions per day.\n\nThe combination of this mutation rate and the enormous number of daily replication events leads to the generation of a staggering number of genetic variants every single day. The population of HIV-1 in a host is not a single, monoclonal entity but a \"cloud\" of many closely related but genetically distinct variants. This heterogeneous and dynamically evolving population is termed a \"quasispecies\".\n\nThe constant introduction of new mutations ($E[M] = 0.291$ per cycle) provides the raw genetic material for evolution. In the host, this viral diversity is subjected to strong selective pressures, most notably the host immune system (e.g., cytotoxic T-lymphocytes and neutralizing antibodies). Most new mutations might be neutral or deleterious, but a small fraction may confer a survival advantage. For instance, a mutation in the viral envelope protein might allow the virus to evade recognition by the immune system (an \"escape mutant\"). Such a variant will be preferentially replicated, leading to its expansion in the quasispecies population.\n\nTherefore, the calculated mutation expectation of $0.291$ is the fundamental engine driving the adaptability of HIV-1. It underpins the virus's ability to evade the immune system, develop resistance to antiretroviral drugs, and alter its cell tropism, all of which are central to the pathology of AIDS. The high mutation input ensures that a diverse portfolio of viral variants is always available, from which selection can favor the fittest in the changing environment of the host.",
            "answer": "$$ \\boxed{0.291} $$"
        },
        {
            "introduction": "The defining feature of AIDS is the catastrophic loss of CD4 T cells, but how exactly do these cells die? This exercise explores the modern understanding that much of this death is due to an inflammatory process called pyroptosis, which affects bystander cells not productively infected with HIV. By analyzing hypothetical assay data from caspase activity and interleukin release, you will practice the quantitative reasoning used in pathology to determine the relative contribution of different cell death pathways, like pyroptosis and apoptosis, to immunodeficiency. ",
            "id": "4426917",
            "problem": "An ex vivo lymphoid-tissue assay investigates the mode of death of cluster of differentiation 4 (CD4) T cells during Human Immunodeficiency Virus (HIV) exposure. Two death pathways are considered: apoptosis and pyroptosis. Use the following foundational definitions and facts as the starting point for your analysis.\n\n- Apoptosis is a programmed, non-inflammatory cell death characterized by activation of caspase-3 (and caspase-7). In bulk assays, total caspase-3 signal is proportional to the number of apoptotic cells.\n- Pyroptosis is an inflammatory cell death mediated by caspase-1 activation downstream of inflammasomes, leading to maturation and release of interleukin-1 beta (IL-1β). In bulk assays, mature IL-1β recovered in the supernatant and caspase-1 activity are both proportional to the number of pyroptotic cells.\n\nIn an experiment with a population of $N = 2.0 \\times 10^{6}$ CD4 T cells exposed to HIV ex vivo for $16$ hours, the following baseline-subtracted measurements were obtained from the supernatant and lysate:\n\n- Caspase-1 activity: $C_{1} = 4.0 \\times 10^{8}$ arbitrary units (AU).\n- Mature interleukin-1 beta (IL-1β) mass: $I = 24 \\ \\mathrm{pg}$.\n- Caspase-3 activity: $C_{3} = 1.2 \\times 10^{7}$ relative fluorescence units (RFU).\n\nSingle-cell calibration standards determined under matched assay conditions are:\n\n- A pyroptotic CD4 T cell contributes $k_{1} = 2.5 \\times 10^{5}$ AU to the caspase-1 assay and releases $q_{\\beta} = 1.5 \\times 10^{-2} \\ \\mathrm{pg}$ of mature IL-1β.\n- An apoptotic CD4 T cell contributes $k_{3} = 2.0 \\times 10^{4}$ RFU to the caspase-3 assay.\n\nAssume that each cell dies through only one pathway (no overlap), non-death contributions to signals are negligible after baseline subtraction, and the calibrations apply linearly to this sample. Using only these premises, compute the proportion of CD4 T cell death attributable to pyroptosis relative to total CD4 T cell death. Express your final answer as a decimal rounded to four significant figures. No units should be included in the final answer.",
            "solution": "The problem requires the computation of the proportion of CD4 T cell death attributable to pyroptosis relative to the total number of dead CD4 T cells. The solution is derived by first calculating the number of cells dying via each specified pathway—pyroptosis and apoptosis—using the provided experimental measurements and single-cell calibration standards.\n\nLet $N_{pyro}$ be the number of cells undergoing pyroptosis, and let $N_{apop}$ be the number of cells undergoing apoptosis. The problem states that each cell dies through only one pathway, so the total number of dead cells, $N_{death}$, is given by the sum:\n$$N_{death} = N_{pyro} + N_{apop}$$\n\nThe proportion of death attributable to pyroptosis, which we will denote as $P_{pyro}$, is then:\n$$P_{pyro} = \\frac{N_{pyro}}{N_{death}} = \\frac{N_{pyro}}{N_{pyro} + N_{apop}}$$\n\nWe must first determine the values of $N_{pyro}$ and $N_{apop}$. The problem is based on the premise that the total measured signal for a given molecular marker is linearly proportional to the number of cells producing that marker.\n\n**1. Calculation of the number of pyroptotic cells ($N_{pyro}$)**\n\nThe problem provides two independent measurements related to pyroptosis: caspase-1 activity ($C_{1}$) and mature IL-1β mass ($I$). We can calculate $N_{pyro}$ from each and verify the consistency of the data.\n\na) Using caspase-1 activity:\nThe total measured caspase-1 activity is $C_{1} = 4.0 \\times 10^{8}$ AU. The contribution from a single pyroptotic cell is $k_{1} = 2.5 \\times 10^{5}$ AU.\nThe number of pyroptotic cells is the total activity divided by the per-cell activity:\n$$N_{pyro} = \\frac{C_{1}}{k_{1}} = \\frac{4.0 \\times 10^{8} \\ \\text{AU}}{2.5 \\times 10^{5} \\ \\text{AU/cell}}$$\n$$N_{pyro} = \\frac{4.0}{2.5} \\times 10^{8-5} \\ \\text{cells} = 1.6 \\times 10^{3} \\ \\text{cells} = 1600 \\ \\text{cells}$$\n\nb) Using mature IL-1β mass:\nThe total measured mass of mature IL-1β is $I = 24 \\ \\mathrm{pg}$. The mass released by a single pyroptotic cell is $q_{\\beta} = 1.5 \\times 10^{-2} \\ \\mathrm{pg}$.\nThe number of pyroptotic cells is the total mass divided by the per-cell mass:\n$$N_{pyro} = \\frac{I}{q_{\\beta}} = \\frac{24 \\ \\mathrm{pg}}{1.5 \\times 10^{-2} \\ \\mathrm{pg/cell}}$$\n$$N_{pyro} = \\frac{24}{1.5} \\times 10^{2} \\ \\text{cells} = 16 \\times 10^{2} \\ \\text{cells} = 1600 \\ \\text{cells}$$\n\nBoth measurements yield an identical result for $N_{pyro}$, confirming the internal consistency of the provided data. We conclude that the number of pyroptotic cells is $N_{pyro} = 1600$.\n\n**2. Calculation of the number of apoptotic cells ($N_{apop}$)**\n\nThe number of apoptotic cells is determined from the total caspase-3 activity, $C_{3}$, and the per-cell contribution, $k_{3}$.\nThe total measured caspase-3 activity is $C_{3} = 1.2 \\times 10^{7}$ RFU. The contribution from a single apoptotic cell is $k_{3} = 2.0 \\times 10^{4}$ RFU.\nThe number of apoptotic cells is the total activity divided by the per-cell activity:\n$$N_{apop} = \\frac{C_{3}}{k_{3}} = \\frac{1.2 \\times 10^{7} \\ \\text{RFU}}{2.0 \\times 10^{4} \\ \\text{RFU/cell}}$$\n$$N_{apop} = \\frac{1.2}{2.0} \\times 10^{7-4} \\ \\text{cells} = 0.6 \\times 10^{3} \\ \\text{cells} = 600 \\ \\text{cells}$$\nSo, the number of apoptotic cells is $N_{apop} = 600$.\n\n**3. Calculation of the proportion of pyroptotic death ($P_{pyro}$)**\n\nNow we can calculate the total number of dead cells:\n$$N_{death} = N_{pyro} + N_{apop} = 1600 + 600 = 2200 \\ \\text{cells}$$\n\nThe proportion of CD4 T cell death attributable to pyroptosis is:\n$$P_{pyro} = \\frac{N_{pyro}}{N_{death}} = \\frac{1600}{2200} = \\frac{16}{22} = \\frac{8}{11}$$\n\nThe problem asks for the answer as a decimal rounded to four significant figures.\n$$P_{pyro} = \\frac{8}{11} \\approx 0.727272...$$\nRounding to four significant figures, we get $0.7273$.\n\nThe initial total cell population, $N = 2.0 \\times 10^{6}$, serves as context for the experimental scale but is not required for calculating the relative proportion of death between the two pathways.",
            "answer": "$$\\boxed{0.7273}$$"
        },
        {
            "introduction": "Diagnosing acute HIV infection requires a keen understanding of the timeline on which different viral and immune markers appear in the blood. This hands-on problem simulates a real-world diagnostic challenge, providing you with serial laboratory data from a newly infected individual. Your task is to apply the Fiebig staging classification, a critical framework in clinical virology, to determine the precise stage of acute infection by synthesizing results from nucleic acid, antigen, and antibody tests. ",
            "id": "4426959",
            "problem": "A cohort participant is monitored with serial laboratory assays after a high-risk exposure to Human Immunodeficiency Virus type 1 (HIV-1). The following assays are performed: a nucleic acid amplification test (NAAT) for HIV-1 ribonucleic acid (RNA), a p24 antigen immunoassay, a third-generation enzyme immunoassay (EIA) for anti-HIV-1 antibodies, a fourth-generation antigen/antibody combination assay, and an HIV-1 Western blot (WB) with individual band reporting for $p24$ (core), $gp41$ (envelope), $gp120/gp160$ (envelope), and $p31$ (pol).\n\nPositivity criteria:\n- HIV-1 RNA is considered positive if the concentration exceeds $50$ copies/mL.\n- p24 antigen is considered positive if the concentration is $\\ge 1.0$ ng/mL.\n- Third-generation EIA and fourth-generation antigen/antibody assays are considered reactive if the signal-to-cutoff ratio $S/C \\ge 1.0$.\n- Western blot is considered positive if at least two of the following bands are present: $p24$, $gp41$, or $gp120/gp160$. The $p31$ band typically appears later in infection.\n\nSerial data:\n- Day $7$:\n  - HIV-1 RNA: $7.5 \\times 10^{3}$ copies/mL.\n  - p24 antigen: $0.2$ ng/mL.\n  - Third-generation EIA: $S/C = 0.2$.\n  - Fourth-generation assay: $S/C = 0.8$.\n  - Western blot: no bands.\n- Day $10$:\n  - HIV-1 RNA: $1.7 \\times 10^{5}$ copies/mL.\n  - p24 antigen: $6.0$ ng/mL.\n  - Third-generation EIA: $S/C = 0.6$.\n  - Fourth-generation assay: $S/C = 2.1$.\n  - Western blot: negative.\n- Day $12$:\n  - HIV-1 RNA: $2.9 \\times 10^{5}$ copies/mL.\n  - p24 antigen: $15$ ng/mL.\n  - Third-generation EIA: $S/C = 1.4$.\n  - Fourth-generation assay: $S/C = 4.5$.\n  - Western blot: indeterminate; single $gp41$ band.\n- Day $15$:\n  - HIV-1 RNA: $3.2 \\times 10^{5}$ copies/mL.\n  - p24 antigen: $18$ ng/mL.\n  - Third-generation EIA: $S/C = 3.5$.\n  - Fourth-generation assay: $S/C = 7.0$.\n  - Western blot: positive for $p24$ and $gp41$; negative for $p31$.\n\nDefinitions of Fiebig staging for acute HIV-1 infection (using classic serologic and virologic sequence):\n- Stage $I$: HIV-1 RNA positive; $p24$ antigen negative; serologic assays negative; Western blot negative.\n- Stage $II$: $p24$ antigen positive while serologic antibody assays remain negative; Western blot negative.\n- Stage $III$: enzyme immunoassay positive; Western blot negative.\n- Stage $IV$: enzyme immunoassay positive; Western blot indeterminate.\n- Stage $V$: Western blot positive without $p31$ band.\n- Stage $VI$: Western blot positive with $p31$ band present.\n\nTask:\nUsing the serial laboratory data and the well-established sequence of biomarker appearance in acute HIV-1 infection, compute the most likely Fiebig stage number on day $15$. Then, infer from first principles of immunopathology what dominant morphologic and immunologic changes are occurring in lymphoid tissue at this stage (do not report these in your final numeric answer).\n\nProvide your final answer as a single integer from $1$ to $6$. No rounding is required. No units should be included in your final answer.",
            "solution": "The problem requires the determination of the Fiebig stage of acute Human Immunodeficiency Virus type 1 (HIV-1) infection for a cohort participant on day $15$ post-exposure, based on provided serial laboratory data and staging definitions. Additionally, an inference of the underlying immunopathological processes at this stage is requested for the reasoning, but not for the final numerical answer.\n\nThe first step is to validate the problem statement.\n\n**Step 1: Extract Givens**\n- **Positivity Criteria:**\n  - HIV-1 RNA: > $50$ copies/mL.\n  - p24 antigen: $\\ge 1.0$ ng/mL.\n  - Third-generation EIA & Fourth-generation assay: Signal-to-cutoff ratio $S/C \\ge 1.0$.\n  - Western blot (WB): Positive if $\\ge 2$ of the following bands are present: $p24$, $gp41$, or $gp120/gp160$.\n\n- **Data for Day $15$:**\n  - HIV-1 RNA: $3.2 \\times 10^{5}$ copies/mL.\n  - p24 antigen: $18$ ng/mL.\n  - Third-generation EIA: $S/C = 3.5$.\n  - Fourth-generation assay: $S/C = 7.0$.\n  - Western blot: Positive for $p24$ and $gp41$; negative for $p31$.\n\n- **Fiebig Stage Definitions:**\n  - Stage $I$: HIV-1 RNA positive; $p24$ antigen negative; serologic assays negative; WB negative.\n  - Stage $II$: $p24$ antigen positive while serologic antibody assays remain negative; WB negative.\n  - Stage $III$: Enzyme immunoassay (EIA) positive; WB negative.\n  - Stage $IV$: EIA positive; WB indeterminate.\n  - Stage $V$: WB positive without $p31$ band.\n  - Stage $VI$: WB positive with $p31$ band present.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, using established biomarkers and the real-world Fiebig staging system for acute HIV-1 infection. The data provided are consistent with the known progression of these markers. The problem is well-posed, objective, and complete, providing all necessary data and definitions to arrive at a unique solution. There are no contradictions, ambiguities, or violations of scientific principles.\n\n**Verdict:** The problem is valid.\n\n**Solution Derivation:**\nTo determine the Fiebig stage on day $15$, we must first interpret the laboratory results for that day using the provided positivity criteria.\n\n1.  **HIV-1 RNA:** The measured concentration is $3.2 \\times 10^{5}$ copies/mL. The positivity criterion is a concentration exceeding $50$ copies/mL. Since $3.2 \\times 10^{5} > 50$, the HIV-1 RNA test is **positive**.\n\n2.  **p24 Antigen:** The measured concentration is $18$ ng/mL. The positivity criterion is a concentration $\\ge 1.0$ ng/mL. Since $18 \\ge 1.0$, the p24 antigen test is **positive**.\n\n3.  **Third-Generation EIA (Antibody Assay):** The measured signal-to-cutoff ratio is $S/C = 3.5$. The criterion for a reactive result is $S/C \\ge 1.0$. Since $3.5 \\ge 1.0$, the third-generation EIA is **reactive (positive)**. This confirms the presence of detectable anti-HIV-1 antibodies.\n\n4.  **Western Blot (WB):** The result is explicitly stated as \"positive for $p24$ and $gp41$\". The positivity criterion is the presence of at least two of the three main bands ($p24$, $gp41$, or $gp120/gp160$). As two bands ($p24$ and $gp41$) are present, the Western blot is correctly interpreted as **positive**. The problem further specifies that the $p31$ band is absent.\n\nCombining these interpretations, the patient's status on day $15$ is:\n- HIV-1 RNA positive\n- p24 antigen positive\n- EIA positive\n- Western blot positive\n- $p31$ band absent on Western blot\n\nNow, we compare this profile with the definitions for each Fiebig stage:\n- **Stage $I$**: Requires a negative p24 antigen and negative serology. This does not match.\n- **Stage $II$**: Requires negative serologic antibody assays. This does not match, as the third-generation EIA is positive.\n- **Stage $III$**: Requires a negative Western blot. This does not match, as the WB is positive.\n- **Stage $IV$**: Requires an indeterminate Western blot. This does not match, as the WB is fully positive. An indeterminate result would be, for example, the presence of only a single band, as was seen on day $12$.\n- **Stage $V$**: Defined as \"Western blot positive without $p31$ band.\" This is an exact match to the patient's status on day $15$. The WB is positive (with bands for $p24$ and $gp41$), and the $p31$ band is explicitly noted as absent.\n- **Stage $VI$**: Requires a positive Western blot with the $p31$ band present. This does not match.\n\nTherefore, the patient is in Fiebig Stage $V$ on day $15$.\n\n**Immunopathological Inference:**\nFiebig Stage $V$ marks a critical point in the host-pathogen interaction during acute HIV-1 infection. The high viral load ($3.2 \\times 10^{5}$ copies/mL) signifies ongoing, massive viral replication, predominantly in lymphoid tissues. The immune system has mounted a substantial response, as evidenced by the laboratory markers. The positivity of the third-generation EIA and the maturation of the Western blot to full positivity (with key bands against core protein $p24$ and envelope protein $gp41$) indicate a robust, diversifying B-cell response producing specific antibodies.\n\nAt the morphological level within lymphoid tissues (e.g., lymph nodes, gut-associated lymphoid tissue), this stage corresponds to florid follicular hyperplasia. Germinal centers are dramatically expanded, filled with proliferating B-cells, helper T-cells, and follicular dendritic cells (FDCs). The FDCs trap vast quantities of virions on their surfaces, creating a concentrated reservoir of antigen that drives B-cell affinity maturation. However, this process is a \"Bermuda Triangle\" for CD4$^+$ T-helper cells, which are also the primary targets of HIV. As they are recruited to the germinal centers to provide help to B-cells, they encounter a high density of virus and are efficiently infected and destroyed. This leads to profound, often silent, depletion of CD4$^+$ T-cells within the lymphoid architecture, even while peripheral blood counts may not yet reflect the full extent of the damage. Concurrently, a virus-specific cytotoxic T-lymphocyte (CD8$^+$ T-cell) response is ramping up, infiltrating these tissues to kill infected cells. This CTL response is primarily responsible for the impending decline of plasma viremia and the establishment of a viral set point. In summary, Fiebig Stage $V$ is characterized by a peak adaptive immune response co-located with maximal viral replication and severe immunopathology in lymphoid organs.\n\nThe computed stage number is $5$.",
            "answer": "$$\\boxed{5}$$"
        }
    ]
}